• Newsroom
  • Toray Licenses RADIFIL® Fast-Dissolving Film Coating Technology to Kishi Kasei

Toray Licenses RADIFIL® Fast-Dissolving Film Coating Technology to Kishi Kasei

Share on facebook Share on twitter Share on Linkedin

Mar. 22, 2021

Toray Industries, Inc.,
Kishi Kasei Co., Ltd.

Tokyo, Japan, March 22, 2021 – Toray Industries, Inc., announced today that it has concluded an agreement to license its RADIFIL® (patent numbers 6443332 and 5696742) fast-dissolving film coating technology to Yokohama-based Kishi Kasei Co., Ltd.

The agreement grants Kishi Kasei the exclusive right to develop, manufacture and sell orally disintegrating tablet coating agents in Japan based on the RADIFIL® technology. That company will also have the right to use the RADIFIL® trademark. Toray will receive considerations including running royalties under this arrangement. Kishi Kasei will start supplying prototype coatings to pharmaceutical manufacturers through this technology transfer and looks to strengthen its pharmaceutical excipients business.

RADIFIL® employs two proprietary coating technologies for orally disintegrating tablets. One lightshields drug tablets containing photodegradable pharmaceutical active ingredients. The other moisture-proofs and creates a gas barrier for drug tablets containing highly hygroscopic active pharmaceutical ingredients. Both technologies maintain tablets’ fast disintegration.

Toray’s RADIFIL® technologies received an Encouragement Prize for Invention from the Japan Institute of Invention and Innovation in 2018 and the 2019 Asahi Kasei Pharmaceutical Technology Award from the Academy of Pharmaceutical Science and Technology.

Patients can take orally disintegrating tablets with or without water. This greatly contributes enhancement in medication compliance for the elderly, who find swallowing harder, and those needing to limit fluid intakes. Toray and Kishi Kasei will keep striving to help maintain and improve consumer health through innovative formulation technologies.

The licensing agreement with Kishi Kasei excludes film-coating technology for tablets containing nalfurafine hydrochloride which is the active ingredient in Remitch® (see note) OD tablets 2.5μg, an oral antipruritus drug for which Toray has obtained a marketing authorization.

RADIFIL® trademark

Note: Remitch® is a registered trademark of Torii Pharmaceutical Co., Ltd.

Profile of Toray Industries, Inc.
Establishment: January 1926
Representative: Akihiro Nikkaku, President and Representative Director
Paid-in Capital: 147.9 billion yen
Head office: Chuo Ward, Tokyo
Number of employees: 48,031 (Group total) (as of March 31, 2020)
Principal businesses: Manufacturing, processing, and selling fibers, resins, films, carbon fiber composites,
electronic materials, pharmaceuticals, and medical equipment

Profile of Kishi Kasei Co., Ltd.
Establishment: May 1953
Representative: Daisuke Maezawa, President
Paid-in Capital: 40 million yen
Business sites: Head office and Yokohama Plant and laboratory
Number of employees: 90
Principal businesses: Manufacturing and selling dyes for food, cosmetics, pharmaceuticals and quasi-drugs,
clinical trial drugs, and other acidic dyestuffs; contract development and manufacturing organization
operations for biopharmaceuticals; and original design manufacturing for cosmetics and biopharmaceuticals
R&D at affiliated companies